An Interview with An Interview with Tony Bihl and Bioventus

Tony Bihl, CEO

2. What do you think is the most important issue today related to osteoarthritis?

Many times, a patient’s knee OA isn’t diagnosed until late stages when treatment options may be limited to more invasive procedures such as knee replacement. The earlier a diagnosis can be made, the more options a patient has to manage their symptoms and possibly avoid an early surgery. With increased awareness and education on the risk and signs of knee OA, we can help individuals delay or even prevent it from progressing.

3. How does your work connect to issues in osteoarthritis?

Our mission is to help people resume active lives and osteoarthritis is a focus for Bioventus. We are committed to providing non-invasive cost-effective treatments for patients suffering from the disease. This extends beyond our product portfolio. Since 2012, we have been an active supporter and member of the Triangle Chapter of the Arthritis Foundation raising thousands of dollars each year for both its annual Walk to Cure Arthritis and more recently the Jingle Bell Run. In addition, I am Triangle Board Chairman and a member of the national Arthritis Foundation Board of Directors. We also provide health care professionals with medical education resources on knee osteoarthritis through www.BioventusAcademy.com and regional medical education events.

4. What is a headline you’d like to see about osteoarthritis in five years?

New treatment identified to prevent and reverse the effects of osteoarthritis.

5. What is one interesting fact you’d like people to know about your organization?

We continue to research and invest in next-generation solutions for reducing pain and solutions that repair cartilage and bone and we believe new breakthroughs for the disease are just around the corner.